Atopic Dermatitis Treatment Landscape

Slides:



Advertisements
Similar presentations
Advancing Care Forward in Squamous Cell Carcinoma of the Head and Neck
Advertisements

Fostering a Collaborative Approach in the Management of BRCA-Mutated Ovarian Cancer.
Chronic HCV Infection and CKD
Immunotherapies: Key Considerations in the Identification and Management of irAEs.
Clinical Trials in IBD.
New Psoriasis Treatments
T-Cell Exhaustion: Can We Overcome It in Cancer?
Advances in Managing Inhibitors in Patients With Hemophilia A
Relapsed/Refractory Follicular Lymphoma Conundrums
Dual Antiretroviral Therapy
Progression After Cancer Immunotherapy in Advanced NSCLC
Atopic Dermatitis Treatment Landscape
Updates in Management of Atopic Dermatitis From Real Patient Cases
Mid-Year Hemophilia Update
Induction Chemotherapy for Patients With High-Risk or Secondary AML
BTK Inhibitors in Relapsed/Refractory Mantle Cell Lymphoma
Differentiating Among the CDK 4/6 Inhibitors in the Management of Metastatic Breast Cancer.
The Resurgence of Topical Treatments Across a Spectrum of Psoriasis
Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.
Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma
Addressing Disease Burden in Asthma
Expert Tips for Tackling Atopic Dermatitis in Pediatric Practice
The Evolving Role of Immunotherapy in NSCLC
Translating Atopic Dermatitis
Addressing Challenges in Factor VIII Inhibitors in Children With Hemophilia.
Postpartum Depression
The Emerging Role of Immunotherapy in Hodgkin Lymphoma
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Next-Gen Psoriasis Therapies:
Evaluating Next-Generation BTK Inhibitors
Case Studies in Unresectable Hepatocellular Carcinoma
Hyperhidrosis Is Burdensome!
Emerging Atopic Dermatitis Treatments:
Essential Concepts in the Use of Immunotherapies in Bladder Cancer
Ask the Experts.
Immunotherapy for cSCC
The JAK-STAT Pathway and Graft-vs-Host Disease
Novel Approaches in T1D Management
Impactful Data in TD That Can Guide Treatment Decisions
New Data on Emerging Treatments for Psoriasis
Advancing Care Across the Spectrum of Pancreatic Cancer
Expert Insights Into the Latest Treatment of Advanced Soft-Tissue Sarcoma.
Evolving Concepts in the Management of Head and Neck Cancers
The Evolving Treatment Landscape in Atopic Dermatitis
Current and Emerging Strategies for Management of Moderate-to-Severe Atopic Dermatitis.
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Expert Perspectives on the Clinical Use of Immune Reconstitution vs Escalation Therapy for MS.
Background. Advancing the Care of Patients With Moderate to Severe Atopic Dermatitis: A Case-Based Discussion.
Parkinson Disease Psychosis
Getting to Grips With the Science of CGRP and Migraine
Advances in Immunotherapy for Peanut Allergy
Immune Checkpoint Inhibitors in Lung Cancer
Advances in Severe Asthma Management
Guide to Atopic Dermatitis
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
The Burden of Psoriasis:
Patient Questions and Expert Answers in Psoriasis:
Biomarker Testing: Harnessing All Sides of the Tumor Microenvironment
The Psychiatrist's Role in Tardive Dyskinesia
Update on the Management of Atopic Dermatitis
Novel Concepts in the Management of RCC
Debates and Dilemmas, Part 1
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.
The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Checkpoint Inhibitors in First-Line Advanced NSCLC
How to Select Therapy in Relapsed/Refractory CLL
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Pathophysiologic Targets of Allergic Asthma
Immune Checkpoint Inhibitors in Lung Cancer
Presentation transcript:

Atopic Dermatitis Treatment Landscape

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Incidence of Atopic Dermatitis

Location, Location, Location

Assessing the Severity of AD Comparing EASI, SCORAD, and IGA

Patient-Reported Burden of AD

Impact of AD on Quality of Life

Impact of AD on Mental Health

Burden of AD

Novel Treatments for AD

CHRONOS: Dupilumab for the Management of Moderate-to-Severe AD

CHRONOS: Dupilumab Efficacy

Dupilumab Increased Incidence of Conjunctivitis

Lebrikizumab

Lebrikizumab Efficacy: Results From TREBLE

Tralokinumab Efficacy

Nemolizumab: IL-31R Targeting Antibody

Nemolizumab Efficacy

JAK Inhibitors

Novel Topical Agents: Crisaborole

Topical JAK Inhibitors

Other Agents in Development for AD

Is the Patient a Candidate for Systemic Treatment

Take-Home Messages